WHAT WE DO AT IC TARGETS
During MRI scans it is sometimes necessary to give the patient a substance to improve the clarity of the images. Such substances are called contrast agents and allow doctors to better identify disease. IC Targets develops a contrast agent helping cardiologists to select the patients benefiting from reopening of cardiac blood veins (revascularisation). This may lead to better care and reduced risk of heart failure. Clinical phase 2 trails are planned started early 2017.
IC Targets also conducts cancer therapy research on an immunostimulating substance called granulocyte colony stimulating factor (G-CSF). Our studies have shown that tumour growth is reduced when G-CSF is packed in small particles and co-administered with therapeutic antibodies. Animal studies are currently conducted in collaboration with French academic partners and the Norwegian Research Council.
The company is based in Oslo, Norway. Oslo is not only the global home of modern contrast agents, but has also a thriving immuno-oncology cluster.